Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study

Post Date: 
2006-09-25
   |   
Countries: 
Publication: 
Archives of Internal Medicine
Summary: 

Background: Treatment of latent tuberculosis infection (LTBI) is an important aspect of tuberculosis control in the United States, but the effectiveness of this strategy is compromised by poor adherence to the recommended 9-month isoniazid regimen. In this study, we compared treatment completion and clinically recognized adverse drug reactions in patients prescribed 9 months of isoniazid therapy or 4 months of rifampin therapy for LTBI.


 


Methods: Retrospective chart review of patients who received LTBI treatment at a public health clinic.

Citation: 
Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, Baruch N, Adelakun A, Dorman SE. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006 Sep 25;166(17):1863-70. doi: 10.1001/archinte.166.17.1863.
Collaborators: 


  • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

  • Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

  • Maryland State Department of Health and Mental Hygiene, Baltimore, MD

  • Prince George's County Tuberculosis Control Program, Cheverly, MD